Form 4: Liquidia CCO Moomaw Granted Significant Equity Awards

Liquidia Corp's Chief Commercial Officer, Scott Moomaw, received substantial equity awards, including Restricted Stock Units and Performance Stock Units, on January 16, 2026.

Summary

• Scott Moomaw, Chief Commercial Officer of Liquidia Corp (LQDA), was granted 32,955 Restricted Stock Units (RSUs) and 49,433 Performance Stock Units (PSUs) on January 16, 2026.
• The RSUs convert into common stock on a one-for-one basis, with 25% vesting on January 11, 2027, and 6.25% vesting every three months thereafter.
• The PSUs also convert into common stock on a one-for-one basis, with 25% vesting on January 11, 2027 (or later, upon the filing of the FY2026 10-K), and 6.25% vesting every three months thereafter.
• PSU vesting is contingent upon a milestone-based condition related to net product sales revenue from YUTREPIA in 2026, as disclosed in the Issuer's FY2026 10-K.
• Following these transactions, Scott Moomaw beneficially owns 187,469 shares of common stock, which includes previously granted unvested RSUs and shares acquired under the Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grants align executive incentives with shareholder interests and specific company performance goals, particularly for the YUTREPIA product.

Positives

• The equity grants, particularly the performance-based PSUs, align the Chief Commercial Officer's incentives directly with the company's strategic goal of increasing YUTREPIA net product sales revenue.
• Granting equity awards is a standard practice that helps retain key executives and aligns their long-term interests with those of shareholders.

Negatives

• The vesting schedules for both RSUs and PSUs are long-term, meaning the executive's full ownership of these shares is deferred over several years.

Risks

• The vesting of Performance Stock Units (PSUs) is tied to the achievement of specific net product sales revenue targets for YUTREPIA in 2026, introducing performance risk related to the commercial success of this product.
• Failure to meet the YUTREPIA sales milestone could result in a forfeiture of a portion of the granted PSUs.

Future Outlook

The grant of performance-based stock units tied to YUTREPIA net product sales revenue in 2026 indicates a strong strategic focus on the commercial success and revenue generation of this specific product in the near future.

Industry Context

Executive equity grants, particularly those with performance-based vesting conditions, are a common compensation strategy in the biotechnology and pharmaceutical industries. This practice aims to incentivize management to achieve key commercial milestones, such as product sales targets, which are crucial for growth in this sector.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Commercial Officer's financial interests with the company's performance, particularly YUTREPIA sales, potentially benefiting shareholder value if targets are met.
• Employees: The grants are part of the executive compensation structure, which can influence overall compensation philosophy within the company.

Next Steps

• Monitoring the vesting schedule of the RSUs, with the initial vesting date set for January 11, 2027.
• Tracking the company's net product sales revenue for YUTREPIA in 2026, as this will determine the vesting of the PSUs, to be disclosed in the FY2026 10-K.

Key Dates

Keywords

Liquidia Corp, LQDA, Scott Moomaw, Chief Commercial Officer, Executive Compensation, Restricted Stock Units, Performance Stock Units, Equity Grant, YUTREPIA, SEC Form 4